- Molecular NamePerindopril
- SynonymPerindopril Erbumine
- Weight368.474
- Drugbank_IDDB00790
- ACS_NO107133-36-8
- Show 3D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)0.7
- pkaN/A
- LogD (pH=7, predicted)-2.54
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)0.43
- LogSw (predicted, AB/LogsW2.0)5.74
- Sw (mg/ml) (predicted, ACD/Labs)43.92
- No.of HBond Donors2
- No.of HBond Acceptors7
- No.of Rotatable Bonds9
- TPSA95.94
- StatusFDA approved
- AdministrationN/A
- PharmacologyA long-acting ACE inhibitor.
- Absorption_value95.0
- Absorption (description)N/A
- Caco_2N/A
- Bioavailability75.0
- Protein binding60.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmExtensively metabolized in liver to active metabolite perindoprilat and other metabolites by glucuronidation and cyclization via dehydration. Two metabolic pathways lead to inactive metabolites: glucuronide compounds and lactam derivatives.
- Half lifePerindopril: 2.9 h (fasted individuals) and 3.4 h (fed). Perindoprilat: 10.9 h (fasted) and 12.0 h (fed). For perindoprilat, the distribution half-life is also reported as 5 h with an elimination half-life of 25 to 30 h.
- ExcretionRenal
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityThe following side effects were reported in clinical trials: cough, back pain, sinusitis, viral infections, hypertonia, dyspepsia, fever, proteinuria, ear infections, palpitations.
- LD50 (rat)N/A
- LD50 (mouse)N/A